Trials / Completed
CompletedNCT02981329
Fetal Hemoglobin Induction Treatment Metformin
Use of Metformin as a Fetal Hemoglobin Inducer in Patients With Hemoglobinopathies
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- Baylor College of Medicine · Academic / Other
- Sex
- All
- Age
- 10 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether metformin is effective in the treatment for sickle cell anemia (SCA).
Detailed description
This is a dose escalation, pilot study for subjects with sickle cell anemia (SCA) disease to determine if metformin has a beneficial effect on the treatment and quality of life of SCA patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Metformin | Metfomin will be taken daily. The metformin dose will be increased during two time points per subject if protocol dose escalation criteria is met. |
| BEHAVIORAL | Questionnaires | Questionnaires will be completed to assess the impact quality of life |
Timeline
- Start date
- 2017-03-02
- Primary completion
- 2020-07-20
- Completion
- 2020-07-20
- First posted
- 2016-12-05
- Last updated
- 2023-10-12
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02981329. Inclusion in this directory is not an endorsement.